MassDevice15m
Supira Medical closes $120M Series E, completes enrollment in ventricular assist device study
Supira Medical announced today that it completed an oversubscribed Series E financing round, bringing in $120 million.
Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States
Supira Medical, Inc. (Supira), a clinical-stage Shifamed portfolio company, today announced the successful completion of an ...
TMCnet2d
Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating biotech and advancing early and late-stage innovative ...
TCTMD4d
Lower Risk of Mortality for Shock Patients Transferred to Expert Centers
The US data also point to lower costs and shorter stays at these expert centers, an argument for regionalized care akin to ...
Frontiers5d
From Laboratory Insights to Clinical Strategies in Cardiogenic Shock
Cardiogenic shock remains a challenging clinical syndrome characterized by critically impaired cardiac output, systemic hypoperfusion, and high mortality ...
TCTMD6d
ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care
In this “data-scarce zone,” the paper offers a road map for the first 24 hours and tips for transfer, teams, and more.